| Source | Latest linked headline | Age |
|---|---|---|
| Nature | WILL THE MRNA FLU SHOT WORK BETTER THAN A REGULAR SEASONAL ONE? WHAT THE SCIENCE SAYS | 20 hrs ago |
Nature published an online article on 13 August 2026 that reviews Moderna’s newly approved mRNA influenza vaccine, noting that the technology could enable manufacturers to respond more quickly to changing influenza strains.
The Nature piece, DOI 10.1038/d41586-026-02502-8, explains that mRNA platforms allow rapid design and production of vaccine antigens compared with traditional egg‑based methods. While the article highlights the potential for faster adaptation, it does not report specific human efficacy data in the summary provided.
Seasonal flu vaccines must be reformulated annually to match circulating strains, and production timelines can limit coverage. An mRNA approach could shorten that cycle, potentially improving public health responses to antigenic drift.